Check out the companies making headlines in midday trading. JPMorgan – The bank fell 5% after revealing that its net interest income could miss Wall Street analysts’ expectations in 2024, despite beating both top and bottom estimates in the quarter. before. CEO Jamie Dimon also emphasized the dangers of inflationary pressure. Wells Fargo – The bank’s shares inched down less than 1% after reporting a drop in net interest income in the first quarter. Wells Fargo beat analysts’ expectations for adjusted earnings and revenue in the first quarter. BlackRock – BlackRock shares fell nearly 2%. The asset manager reported total net inflows below expectations per StreetAccount. BlackRock posted first-quarter adjusted earnings of $9.81 per share on revenue of $4.73 billion, higher than the $9.35 per share on revenue of $4.68 billion that analysts led by LSEG, formerly Refinitiv, forecast. Globe Life – Life insurance stocks rose 10% after plummeting more than 50% in Thursday’s trading session. The slide was sparked by a report from Fuzzy Panda Research, in which the company disclosed a short position in the stock and made allegations of insurance fraud. Paramount – The entertainment company fell nearly 2% after revealing plans to reduce its board to seven directors from 11. Paramount is currently in talks about a merger with Skydance Media. Corteva – The agricultural chemicals stock lost 3.8% after JPMorgan downgraded it to neutral due to overweight. The company said the stock is not worth buying ahead of the first-quarter earnings report due to an expected decline. Ciena – Shares fell nearly 3% after Citi initiated coverage of the software company with a sell rating. The bank said investors were too optimistic about the potential of artificial intelligence, which was further than they expected. Zoetis – The pet medicine company fell more than 7%. The drop comes after a report from The Wall Street Journal looking at potential side effects from Zoetis’ arthritis drugs Librela and Solensia. Arista Networks – Shares fell 9% after a double downgrade at Rosenblatt to sell from buy. Arista’s AI opportunity may be smaller than expected, the company warns. – CNBC’s Michelle Fox, Alex Harring, Tanaya Macheel and Pia Singh contributed reporting.